[PRACTICE NOTE] Experience Alpha Through Customers for Life Marketing

Experience alpha is the increment in realized value a commercial system produces above what the same brand, the same product and the same spend would have returned without the experience. In pharma that increment is recovered rather than invented, and the field is where most of it sits.

Organizations are measured on what they can start and rarely on what they can finish. Budget cycles reward created demand because created demand is visible inside a quarter, while the slower work of seeing a decision through leaves a thinner trail. Most commercial planning prices the first half of the job accurately and the second half barely at all.

In pharmaceuticals that asymmetry carries a sharper edge, because a manufacturer does not control the transaction between its science and the person who needs it. A written prescription is intent rather than realized value, and intent has to survive a fulfillment process, a benefit design and a year of ordinary life before it becomes therapy. Intent is fragile in ways spend reports never show. The commercial system that earned the intent is often not the system resourced to protect it.

What alpha means when it is borrowed carefully

Alpha in capital markets is a precise term rather than a flourish. It names the excess return an investment produces above its index, once the market's own contribution has been accounted for. A manager whose return merely matches the index has produced none of it, whatever the headline number looks like. Alpha is a residual rather than a result.

In The Customer Excellence Enterprise I carried that term across into customer relationships and named the result experience alpha. Applied to a customer-centric commercial organization, experience alpha is the increment in realized value above what the same brand, the same product and the same spend would have produced without the experience. The benchmark is the organization's own counterfactual rather than a competitor, which is what makes the measure both uncomfortable and useful.

The retention arithmetic underneath the claim

The economics beneath experience alpha will be familiar to anyone who has read a loyalty study. The cost to acquire a new customer runs five to twenty-five times the cost to retain one. It is far too costly for companies to be caught in a vicious cycle of continuously acquiring new customers while existing ones are disenfranchised.

In pharma the equivalent is a brand that keeps generating new prescribing intent while the intent it already earned quietly fails to become therapy. The spend that created the first prescription is counted, the abandonment that follows is absorbed, and the next campaign is briefed to create more intent. Fred Reichheld made the original loyalty case two decades ago in Harvard Business Review, and the arithmetic has not moved since.

Two questions that leaders tend to merge

The alpha question and the capital question are related and separate, and most commercial reviews collapse them into one. The alpha question asks for the increment above a benchmark, which is a question about effect. The capital question asks what multiple of the investment returns, which is a question about efficiency. Effect and efficiency are different tests. A system can produce real alpha and still return a poor multiple, and the reverse happens just as often.

Coverage, hit rate and velocity

The multiple decomposes into three terms that commercial leaders already recognize in other contexts. Coverage is the share of consequential moments the system actually reaches, which is a question of reach rather than activity. Hit rate is the share of those moments where the intervention changes the outcome. Velocity is how quickly that change shows up as progression once the intervention lands.

Each term fails differently, which is the practical value of holding them apart. A system with wide coverage and a low hit rate is busy and largely inert, and its reports will look healthy for some time. Diagnosing which of the three is binding usually matters more than another increase in effort.

Cycle time as compounding frequency

Cycle time is the fourth term, and it measures nothing about the quality of a single loop. It sets how many times a year that loop runs, which makes it the compounding frequency of the whole multiple. Treating it as an operational detail leaves the most leveraged variable in the model unattended.

A field organization that detects a barrier, assigns it and closes it inside a month compounds its learning twelve times in a year, while one that takes a quarter compounds four. The second organization may look identical on a coverage report and will return a materially smaller multiple on the same investment. In the organizations I have worked inside, cycle time is where the difference between two similar field models tends to live.

The arithmetic that makes the alpha real

The share of earned value that becomes sustained therapy is the Realization Rate. Customer Value at Risk is earned value multiplied by one minus that rate, which turns a value leakage story into an exposure figure a finance partner can test. Experience alpha is the recovered portion of that exposure, which is precisely why it competes for capital against the alternative of creating more intent.

Work published with TheyDo traced the sequence as an illustrative compounded scenario rather than a benchmark. A billion dollars of earned value becomes roughly seven hundred million after prescriptions that are never filled, less again after early discontinuation, and close to four hundred and fifty million in realized value once long term adherence erosion is counted. No competitor takes the difference.

That shape carries a repricing argument worth stating plainly. If less than half of created intent survives to realization, the marginal dollar spent protecting existing intent now earns more than the marginal dollar spent creating more of it. The case for a commercial return on experience rests on that comparison rather than on sentiment about customers.

Ideal Experience Attributes carry the increment

Alpha of this kind rarely arrives from a campaign, because it is produced by how an organization shows up. The construct is Ideal Experience Attributes, five to seven of them, defined by the organization rather than imported from a consumer category. They are attributes rather than principles, and the distinction matters because an attribute can be trained, observed and measured.

In the book I worked through seven attributes that turn helpfulness into preference, namely empathy, context, reciprocity, relevance, differentiation, goodwill and trust. A pharma organization tends to arrive at a different set, because its moments sit inside a clinical workflow rather than a retail one. The discipline is the same, and naming them is what makes them part of the company's DNA rather than part of a deck.

Training and measuring for named attributes is what moves them from language into behavior, and behavior is what a customer experiences as character. In our work those attributes are embedded in FieldOS, the operating blueprint for field intelligence and activation. Its closed loop runs in six stages, Capture Signal, Classify Barrier, Assign Owner, Intervene, Measure Progression, then Learn and Improve.

Preference is the payoff and goodwill is the balance

Preference is earned, never granted. It is what the attributes buy, and it behaves as a leading indicator rather than a lagging one. The level and intensity of preference across a customer portfolio signals current performance and the prospect of earning enduring relationships. In a clinical setting preference shows up as the therapy a prescriber reaches for when the week is crowded and the tolerance for administrative risk is thin.

Goodwill is the running balance behind that preference, a virtual account that takes deposits when experiences land and debits when they do not. No commercial system is perfect, so the balance largely determines whether a customer grants the benefit of the doubt after an inevitable misstep. Bain is blunt about the limit of that balance, describing goodwill as "a necessary but insufficient condition for generating revenue growth."

The conversion from goodwill into revenue has to be designed, and that design lives after the clinical decision rather than before it. Gartner has found that low effort customers are 61% more likely to stay with a company, which is the kind of leading signal a progression measure is built to catch. Forrester reported that customer obsessed organizations saw 41% faster revenue growth than the rest.

A contrarian claim about the field in the age of AI

This argument reaches a conclusion about the field that runs against the direction of much current planning. The field is the most expensive channel in pharma and also the most brand-defining, because it is where a company is experienced as a character rather than as a message. Character is harder to copy than a message. Channels that carry that much brand weight are candidates for reassertion rather than quiet reduction.

AI did not replace the field organization, it made it more valuable than ever, because the scarce input is now observed context rather than another message. AI will not make a fragmented commercial model customer-centric, since it makes whatever operating system already exists faster and more scalable. A fragmented system with better models often produces faster fragmentation.

That is why field force effectiveness deserves to be reframed as a value realization question rather than an activity question. The frontline is one of pharma's most underutilized intelligence systems, encountering barriers long before dashboards detect them. The paper carrying this argument in full is titled The Field Multiple, and the multiple is the capital half of the case.

What changes once the increment is measured

Every interaction either compounds value or creates drag, which is the plainest statement of the tenet beneath all of this. Once an organization can name its Realization Rate, its exposure and the increment its experience produces, the discussion stops depending on conviction. A finance partner can argue with a number rather than with a belief.

None of this reflects a shortage of patient commitment. Patient centricity is native to the industry, and the change in front of it is entering an arena where people have choice and compare what they are given. Experience is the third leg of the value proposition alongside product and brand, and it is the leg that was never deliberately built.

Key Takeaways

• Experience alpha is the increment in realized value above what the same brand, product and spend would have produced without the experience.
• The alpha question and the capital question are separate, and merging them hides which half of a field investment is underperforming.
• The field multiple decomposes into coverage, hit rate and velocity, with cycle time acting as the compounding frequency of the whole.
• Customer Value at Risk is earned value multiplied by one minus the Realization Rate, and experience alpha is the recovered portion of that exposure.
• If less than half of created intent survives to realization, protecting existing intent earns more at the margin than creating more of it.
• Ideal Experience Attributes, five to seven of them, become part of a company's DNA only when they are trained for and measured.

Diagnostic Questions to Consider

1. State the Realization Rate of your lead brand and the Customer Value at Risk that follows from it.
2. Separate your field investment case into the increment it produces above a benchmark and the multiple it returns on capital.
3. Decompose that multiple into coverage, hit rate and velocity, and name which of the three is currently binding.
4. Measure the cycle time between a barrier being observed in the field and a measured change in progression.
5. Name the five to seven Ideal Experience Attributes your organization trains for, and state how each one is observed.

Closing Reflection

The pull toward acquisition is structural rather than foolish, because created demand is easier to attribute and easier to defend in a planning meeting. Protected value leaves a quieter trail, and quiet trails lose budget arguments to loud ones. Experience alpha exists to give the quieter half of the work a number that survives the same scrutiny.

What makes this more than a measurement exercise is where the recovered value actually comes from. It was already earned, by the science, by the brand and by the clinical decision somebody made in good faith. Allowing it to dissipate in a fulfillment process or a crowded clinical week is the most expensive thing a commercial system can do without anyone noticing. Nobody else collects it.

The field is the channel standing closest to that dissipation, which is why the age of AI makes it more consequential rather than less. A capable field organization that sees barriers early and closes them quickly compounds value that no campaign can create a second time. That is the argument, and the arithmetic is now available to test it.

About the Author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.